Drug intelligence / Profile preview

PasterVac THYMO

Development stage: Unknown
Lead developer: Dalat Pasteur Vaccines
Modality: Recombinant Proteins and Enzymes, Peptides
Administration: Oral

Overview

PasterVac THYMO is an oral health supplement developed and manufactured by Dalat Pasteur Vaccines (DAVAC) in Vietnam. Registered as a nutraceutical (thực phẩm bảo vệ sức khỏe), it is marketed for general immune support and strengthening the body's resistance. While the manufacturer does not specify a precise molecular target, the product name strongly suggests the inclusion of thymomodulin, a calf thymus-derived lysate commonly used in Southeast Asia to modulate immune responses by promoting T-lymphocyte maturation and enhancing phagocytic activity. It is intended for individuals with poor immunity or those recovering from illness, rather than as a therapeutic pharmaceutical for a specific disease.

Brand names: PasterVac THYMO

Targets

CD40 (Cluster of differentiation 40 receptor)

Beyond the preview

Go deeper on PasterVac THYMO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PasterVac THYMO.